Key result
Talazoparib induces a sustained response in a child with refractory neuroblastoma and a BARD1 mutation.
Why the study?
Some neuroblastomas carry disabling mutations in BARD1, a homologous recombination repair gene, but response to PARP inhibition in this context is not well described.
Does talazoparib improve response in a child with refractory neuroblastoma and a BARD1 mutation?
Does talazoparib improve response in a child with refractory neuroblastoma and a BARD1 mutation?
Talazoparib may provide a sustained response in patients with refractory neuroblastoma carrying a BARD1 mutation.
Observed response suggests potential but should not change practice; leaves open efficacy of PARP inhibition in BARD1-mutated neuroblastoma.
Some neuroblastomas carry disabling mutations in BARD1 , a homologous recombination repair gene. A child with refractory neuroblastoma and a BARD1 mutation had a sustained response after treatment with the PARP inhibitor talazoparib.
No takes yet. Share an insight, caveat, or question.
Cupit-Link et al. (2024) studied this question. The PARP inhibitor talazoparib induced a sustained response in a child with refractory neuroblastoma and a BARD1 mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: